SHMT2 and central nervous system cancer: Zhang et al. (2022) found that SHMT2 was upregulated in oral squamous cell carcinoma and that strong expression was linked to poor prognosis. More importantly, the role of SHMT2 has been reported in glioma (Kim et al., 2015), lymphoma (Wilke et al., 2022) and bladder cancer (Zhang & Yang, 2021).